Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on July 3, 2024, with the report date of July 5, 2024. The filing addresses the termination of a material definitive agreement regarding a potential equity financing arrangement.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The only financial data points disclosed relate to the terminated financing agreement:
- Proposed Aggregate Proceeds: Up to $621,000.
- Proposed Share Count: Up to 95,833 shares of Common Stock.
- Agreed Purchase Price: $6.48 per share (adjusted for a 1-for-9 reverse stock split effective July 5, 2024).
- Market Price at Termination: $5.23 per share (closing price on July 3, 2024).
Material Changes
The primary material change reported is the termination of the Purchase Agreement entered into on May 16, 2024, with Triton Funds LP. The Company elected to terminate the agreement effective immediately on July 3, 2024. No shares were sold or purchased under the agreement prior to termination. The decision was driven by the Board of Directors' determination that pursuing alternative financing was in the best interest of the Company and its stockholders, particularly given the trading price of the Common Stock fell below the agreed purchase price.
Guidance, Outlook, and Management Commentary
Management, represented by the Board of Directors, stated that terminating the agreement was advisable to pursue alternative financing options. The filing references a press release issued on July 5, 2024, for further details but does not provide specific forward-looking guidance, risk factors, or contingencies beyond the immediate need for alternative capital.
Key Facts for Investor Verification
- Verify the status of the Company's alternative financing efforts following the termination of the Triton agreement.
- Confirm the effective date and impact of the 1-for-9 reverse stock split mentioned in the filing (effective July 5, 2024).
- Review the July 5, 2024 press release (Exhibit 99.1) for additional context on the Board's rationale and future capital strategy.
- Monitor the Company's cash runway and liquidity position given the failure to secure the $621,000 in proposed proceeds.